Research
Hormonal
GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.
GLP-1 and GIP/GLP-1 agonists offer significant cardiovascular and renal benefits, reducing the risk of heart attacks, strokes, and heart failure hospitalizations. These benefits occur independently of weight loss, suggesting direct protective effects on organs. They are recommended for patients with obesity and cardiovascular disease or heart failure.
StrongSupportsVERY_HIGH confidence
Beyond weight reduction, these therapies demonstrate clinically meaningful cardiovascular and renal benefits, some appearing at least partly independent of weight loss, suggesting direct organ-protective effects.
Why this rating
Supported by large cardiovascular outcome trials (LEADER, SELECT, SURPASS-CVOT).
Source
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Jang Won Son · Journal of Korean Medical Association · 2026
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →